Introduction: We describe the clinical features, outcome and incidence of druggable targets of lung cancers in patients ≤ 40 years old.
Materials & methods: Young patients were compared with two other groups (41-64 and ≥ 65 years). Neuroendocrine tumors, adenocarcinoma and non-adenocarcinoma/unspecified non-small-cell lung cancer were analyzed separately. Molecular characteristics of adenocarcinoma were evaluated in a subset of young patients.
Results: Of 2847 patients with lung cancer, 100 were ≤ 40 years old. The young group contained more women, never-smokers and patients presenting with advanced disease. The commonest tumor in young patients was adenocarcinoma. In total, 19 of 34 young patients with adenocarcinoma had tumors with specific molecular alterations.
Conclusion: Lung cancers in young patients have distinctive features but outcomes similar to those in older patients.
Keywords: carcinoid; lung cancer; molecular features; neuroendocrine; young patients.